睿知中国医院研究地图
候选清单

南京南京大学

东部战区总医院(金陵医院)

Jinling Hospital

在本站收录的 53 种疾病中,这家医院列在其中 18 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

东部战区总医院(金陵医院)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma9 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma23 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer20 篇牵头论文牵头 1 项开放试验
  4. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  5. 骨肉瘤Osteosarcoma14 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 多发性骨髓瘤Multiple myeloma4 篇牵头论文牵头 1 项开放试验
  8. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome0 篇牵头论文
  9. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  10. IgG4相关性疾病IgG4-related disease0 篇牵头论文牵头 1 项开放试验
  11. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  12. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  13. Alport 综合征Alport syndrome5 篇牵头论文
  14. IgA 肾病IgA nephropathy10 篇牵头论文
  15. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  16. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  17. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa0 篇牵头论文
  18. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、范可尼贫血、视神经脊髓炎谱系疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、戈谢病、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.3%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 0020232024: 1120242025: 222025

南京有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题手术影像与人工智能分子标志物与基因
论文中的科室消化/肝病科放疗科
牵头的论文9
  1. Effects of immunoenteric nutrition versus general enteral nutrition on prognosis in patients with squamous cell carcinoma undergoing radical esophagectomy post neoadjuvant chemotherapy.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  2. Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study.2025JMIR cancer免费全文
  3. Berbamine promotes ferroptosis of esophageal squamous cell carcinoma by facilitating USP51-mediated GPX4 ubiquitination and degradation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Regulation of IncRNA ZNF667-AS1 in Proliferation and Invasion of Esophageal Squamous Cell Carcinoma Cells via Mediating ceRNA Network.2022Critical reviews in eukaryotic gene expression
  5. A RASSF8-AS1 based exosomal lncRNAs panel used for diagnostic and prognostic biomarkers for esophageal squamous cell carcinoma.2022Thoracic cancer免费全文
  6. Long-term outcomes of robotic-assisted versus thoraco-laparoscopic McKeown esophagectomy for esophageal cancer: a propensity score-matched study.2021Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  7. Development and validation of a new clinical staging system to predict survival for esophageal squamous cell carcinoma patients: Application of the nomogram.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  8. Risk prediction nomogram for major morbidity related to primary resection for esophageal squamous cancer.2021Medicine免费全文
  9. Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.2021Medicine免费全文
PubMed 以外找到的论文(未计入)3
  1. 235. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY2024Diseases of the Esophagus论文
  2. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  3. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgery论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.2%。

牵头论文
23
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 2220222023: 6620232024: 5520242025: 442025

南京有 7 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
    分期
    不分期
    开始
    2025-12
    登记号
    NCT07769827

    年龄 18 岁 至 未注明(登记的条件)

    牵头:东部战区总医院(金陵医院)南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物影像、人工智能与早期发现复发与预后
论文中的科室肿瘤内科影像/核医学科消化/肝病科放疗科

这些论文过半是实验室或动物研究。

牵头的论文23
  1. Etomidate Improves Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells.2026Cellular and molecular gastroenterology and hepatology免费全文
  2. Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.2025BMC cancer免费全文
  3. Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  4. Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma.2025International journal of immunopathology and pharmacology免费全文
  5. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.2025The Lancet. OncologyRCT
  6. A novel single-cell model reveals ferroptosis-associated biomarkers for individualized therapy and prognostic prediction in hepatocellular carcinoma.2024BMC biology免费全文
  7. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma.2024Biochemical and biophysical research communications
  8. Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial.2024ESMO open免费全文
  9. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.2024Frontiers in immunology免费全文
  10. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.2024Journal of gastrointestinal cancer
  11. Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma.2023Applied biochemistry and biotechnology免费全文
  12. Identification of Key Biomarkers in Hepatocellular Carcinoma Induced by Non-alcoholic steatohepatitis or Metabolic Syndrome via Integrated Bioinformatics Analysis.2023Cellular and molecular biology (Noisy-le-Grand, France)
  13. Insights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development.2023Frontiers in bioscience (Landmark edition)
  14. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  15. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.2023Lancet (London, England)RCT
  16. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.2023Lancet (London, England)RCT
  17. Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.2022Integrative cancer therapies免费全文
  18. Radiomics-based MRI for predicting Erythropoietin-producing hepatocellular receptor A2 expression and tumor grade in brain diffuse gliomas.2022Neuroradiology
  19. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer.2021Acta biomaterialia
  20. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  21. Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis.2021Human cell
  22. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance.2021Human cell
  23. Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer.2021Journal of colloid and interface science
中文论文(未计入)2
  1. [Evolution of clinical guidelines for primary liver cancer in China: insights into the development of hepatocellular carcinoma management].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Analysis of the incidence of low viral load/low-level viremia and its associated factors in patients with HBV-related primary liver cancer].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC正在招募NCT07769827牵头方不分期2025-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.2%。

牵头论文
20
2021–2025 年
牵头试验
11
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 4420232024: 8820242025: 222025

南京有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07615907

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:东部战区总医院(金陵医院)南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题营养与康复手术化疗与综合治疗
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科影像/核医学科
牵头的论文20
  1. FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation.2025Digestive diseases and sciences
  2. LDH and glycolytic activity as predictors of immunotherapy response in gastric cancer: a systematic review and meta-analysis.2025Frontiers in immunology免费全文
  3. Effect of nutrition-based prehabilitation on the postoperative outcomes of patients with esophagogastric cancer undergoing surgery: A systematic review and meta-analysis.2024Cancer medicine免费全文
  4. The RNA m6A reader IGF2BP3 regulates NFAT1/IRF1 axis-mediated anti-tumor activity in gastric cancer.2024Cell death & disease免费全文
  5. Phase angle - A screening tool for malnutrition, sarcopenia, and complications in gastric cancer.2024Clinical nutrition ESPEN
  6. Unraveling the immunogenic cell death pathways in gastric adenocarcinoma: A multi-omics study.2024Environmental toxicology
  7. Impact of body composition, grip strength, and physical performance on clinical outcomes for locally advanced gastric cancer during neoadjuvant chemotherapy: A prospective cohort study.2024Nutrition (Burbank, Los Angeles County, Calif.)
  8. Comparison of bioelectrical impedance analysis and computed tomography for the assessment of muscle mass in patients with gastric cancer.2024Nutrition (Burbank, Los Angeles County, Calif.)
  9. Short-Term Prognostic Effect of Comprehensive Complication Index in Patients With Gastric Cardia Adenocarcinoma.2024The Journal of surgical research
  10. Efficacy of Magnifying Endoscopy with Narrow-Band Imaging in the Diagnosis of Early Gastric Cancer and Gastric Intraepithelial Neoplasia.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  11. Effects of oral immunonutritional supplement on 3-year disease-free survival in gastric cancer patients with pathological stage III after total gastrectomy (CRUCIAL): study protocol of a multicentre, randomised clinical trial.2023BMJ open免费全文
  12. Serum ferritin is associated with sarcopenia and predicts long-term survival for gastric cancer undergoing radical gastrectomy.2023European journal of gastroenterology & hepatology
  13. Long-term survival outcome of locally advanced gastric cancer patients who achieved a pathological complete response to neoadjuvant chemotherapy.2023International journal of clinical oncology
  14. Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions.2023Saudi medical journal免费全文
  15. The application value of preoperative fat-free mass index within Global Leadership Initiative on Malnutrition-defined malnutrition criteria for postoperative outcomes in patients with esophagogastric cancer.2022Nutrition (Burbank, Los Angeles County, Calif.)
  16. Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.2022Pathology oncology research : POR免费全文
  17. Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.2021Anticancer research
  18. Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy.2021European radiology免费全文
  19. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.2021Future oncology (London, England)免费全文
  20. Long-Term Outcome in Gastric Cancer Patients with Different Body Composition Score Assessed via Computed Tomography.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer即将招募NCT07615907牵头方不分期2026-05 启动
  2. ONS in Gastric Cancer After Total Gastrectomy状态不明NCT05823272牵头方不分期2024-03 启动
  3. Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer状态不明NCT05253716牵头方不分期2022-08 启动
  4. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729牵头方不分期2017-06 启动
  5. Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer状态不明NCT02949258牵头方II期2017-01 启动
  6. Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients状态不明NCT02338518牵头方III期2015-01 启动
  7. Early Jejunostomy Nutrition Minimizes Time to Chemotherapy状态不明NCT01766765牵头方IV期2013-04 启动
  8. A Novel Nomogram to Predict the Postoperative Overall Survival in Gastrointestinal Cancer Patients已完成NCT05620537牵头方(推断)2022-11 启动
  9. Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy已完成NCT03238404牵头方(推断)不分期2015-08 启动
  10. ERAS for Patients Received Neoadjuvant Chemotherapy已完成NCT03272984牵头方(推断)不分期2015-04 启动
  11. Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study已完成NCT03238820牵头方(推断)不分期2014-01 启动
  12. Development of a Multimodal AI System for GIST Management已完成NCT07454967研究中心2026-03 启动
  13. Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center Study状态不明NCT03236051研究中心不分期2017-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 4 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 4420242025: 222025

南京有 25 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
牵头的论文14
  1. Inhibition of circ_0127646 Enhanced the Cisplatin Sensitivity in Osteosarcoma Cells via miR-22/KAT6B Axis.2025Journal of biochemical and molecular toxicology
  2. An analysis of extraskeletal osteosarcoma based on the literature.2025Scientific reports
  3. Survival outcomes of patients with brain metastasis of osteosarcoma can be improved by aggressive multi-disciplinary interventions including chemotherapy.2024British journal of neurosurgery
  4. An interactive dose optimizer based on population pharmacokinetic study to guide dosing of methotrexate in Chinese patients with osteosarcoma.2024Cancer chemotherapy and pharmacology
  5. Circular RNA CircSATB2 facilitates osteosarcoma progression through regulating the miR-661/FUS-mediated mRNA of ZNFX1.2024Cellular signalling
  6. FRS2 regulated by miR-429 and miR-206 promotes angiogenesis in osteosarcoma.2024Gene
  7. Identification of RALA as a Therapeutic Target and Prognostic Predictor of Osteosarcoma.2023BioMed research international
  8. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.2023Cell death & disease
  9. Injectable rhein-assisted crosslinked hydrogel for efficient local osteosarcoma chemotherapy.2023International journal of pharmaceutics
  10. A case report of rib osteosarcoma and literature review.2023The clinical respiratory journal
  11. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.2022Computational and mathematical methods in medicine
  12. Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling.2022Molecular cancer
  13. Sensitive osteosarcoma diagnosis through five-base telomerase product-triggered CRISPR-Cas12a enhanced rolling circle amplification.2021Analytical methods : advancing methods and applications
  14. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.2021Biochemical and biophysical research communications
早期论文(2016–2020 年)11
  1. MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop.2020Cancer research
  2. miR-139 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1.2019Frontiers in bioscience (Landmark edition)
  3. The application of 3D-printed titanium mesh in maxillary tumor patients undergoing total maxillectomy.2019Journal of materials science. Materials in medicine
  4. Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells.2019Oncology reports
  5. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.2017Cancer letters
  6. SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.2017DNA and cell biology
  7. Personalized Identification of Differentially Expressed Modules in Osteosarcoma.2017Medical science monitor : international medical journal of experimental and clinical research
  8. Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.2016International journal of biological sciences
  9. Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.2016Orthopaedic surgery
  10. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma.2016Orthopaedic surgery
  11. MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6.2016Protein & cell
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)已完成NCT05277480研究中心II期2022-03 启动
  2. A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma状态不明NCT01002092研究中心II期2009-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 11 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025

南京有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
    分期
    未注明
    开始
    2010-07
    登记号
    NCT04210791

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:东部战区总医院(金陵医院)南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题肾脏与骨骼并发症诊断、微小残留病与危险分层双抗与抗体药物
论文中的科室风湿免疫科
牵头的论文4
  1. The impact of CD81 on immune cells and clinical prognosis in multiple myeloma.2025Annals of hematology免费全文
  2. Clinicopathological characteristics of light chain proximal tubulopathy: a multicentre case series.2025Journal of clinical pathology
  3. Identification of the CD16low CD56low CD38pos Natural Killer Cell as a Key Subset in Patients with Multiple Myeloma.2022Iranian journal of immunology : IJI
  4. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.2021Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation状态不明NCT06324266牵头方II/III期2023-04 启动
  2. Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma状态不明NCT02248428牵头方III期2012-04 启动
  3. Autologous Stem Cell Transplantation for Patients With AL Amyloidosis邀请入组NCT04210791牵头方(推断)2010-07 启动
  4. Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.状态不明NCT02086942牵头方(推断)II期2013-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年没有牵头非典型溶血性尿毒症综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南京有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年没有牵头IgG4相关性疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
    分期
    I期
    开始
    2024-03
    登记号
    NCT06285279

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:东部战区总医院(金陵医院)南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases正在招募NCT06285279牵头方(推断)I期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

南京有 15 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

南京有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 5 篇,占 8.6%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

南京有 2 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文5
  1. Genetic features and kidney morphological changes in women with X-linked Alport syndrome.2023Journal of medical genetics
  2. Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis.2023Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  3. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.2022Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  4. Establishment of the induced pluripotent stem cell line (NCKDi005-A) from a male patient with Alport syndrome carrying a homozygous frameshift mutation in the COL4A4 gene.2022Stem cell research
  5. Generation of the induced pluripotent stem cell line (NCKDi004-A) from a 17-year-old patient with Alport syndrome carrying a homozygous mutation in COL4A3 gene.2021Stem cell research
中文论文(未计入)2
  1. [A case of X-linked Alport syndrome with esophageal leiomyomatosis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Precision diagnosis and therapeutic intervention of Alport syndrome].2024Zhonghua yi xue za zhi
早期论文(2016–2020 年)3
  1. Generation of induced pluripotent stem cell line (NCKDi001-A) from a 19-year-old patient with a novel COL4A5 gene mutation in Alport syndrome.2020Stem cell research
  2. Three Novel Heterozygous COL4A4 Mutations Result in Three Different Collagen Type IV Kidney Disease Phenotypes.2018Cytogenetic and genome research
  3. Novel mutations in COL4A3, COL4A4, and COL4A5 in Chinese patients with Alport Syndrome.2017PloS one
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Effects of Dapagliflozin on Progression of Alport Syndrome状态不明NCT06226896牵头方(推断)2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.4%。

牵头论文
10
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 4420232024: 2220242025: 002025

南京有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文10
  1. The prognostic value of hyperhomocysteinemia in IgA nephropathy.2026International urology and nephrology
  2. Development and External Validation of a Multidimensional Deep Learning Model to Dynamically Predict Kidney Outcomes in IgA Nephropathy.2024Clinical journal of the American Society of Nephrology : CJASN
  3. Advancing the application of the analytical renal pathology system in allograft IgA nephropathy patients.2024Renal failure
  4. Clinicopathological features and long-term prognosis of glomerular diseases associated with mercury-containing cosmetics.2023Journal of nephrology
  5. Clinical characterization of polycythemia vera associated with IgA nephropathy in a single Chinese center: A case series.2023Medicine
  6. Primary Cutaneous Mucormycosis Caused by Rhizopus oryzae in a Pediatric Patient with IgA Nephropathy.2023Mycopathologia
  7. The Spectrum of Biopsy-Proven Kidney Diseases, Causes, and Renal Outcomes in Acute Kidney Injury Patients.2023Nephron
  8. Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.2022BMC nephrology
  9. Clinical and morphologic spectrum of renal involvement in idiopathic hypereosinophilic syndrome.2021Clinical and experimental nephrology
  10. Use of liquid chromatography-tandem mass spectrometry to perform urinary proteomic analysis of children with IgA nephropathy and Henoch-Schönlein purpura nephritis.2021Journal of proteomics
中文论文(未计入)1
  1. [Clinicopathological significance and prognostic value of serum 25-hydroxyvitamin D3 level in children with IgA vasculitis nephritis].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
早期论文(2016–2020 年)11
  1. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.2020BMC nephrology
  2. Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement.2020Clinical and experimental medicine
  3. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy.2020EBioMedicine
  4. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.2020Journal of nephrology
  5. Identification of glomerular lesions and intrinsic glomerular cell types in kidney diseases via deep learning.2020The Journal of pathology
  6. [The pathological evaluation of IgA nephropathy].2020Zhonghua yi xue za zhi
  7. Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy.2019American journal of kidney diseases : the official journal of the National Kidney Foundation
  8. [Clinicopathologic features and prognosis of patients with IgA nephropathy superimposed on transplant glomerulopathy].2019Zhonghua yi xue za zhi
  9. Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Schönlein purpura)-related nephritis: a cohort in the adult Chinese population.2018BMC nephrology
  10. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.2017American journal of kidney diseases : the official journal of the National Kidney FoundationRCT
  11. Identification of G8969>A in mitochondrial ATP6 gene that severely compromises ATP synthase function in a patient with IgA nephropathy.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy已完成NCT01451710牵头方(推断)不分期2011-03 启动
  2. Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy已完成NCT00301600牵头方(推断)不分期2003-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 3 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 4 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年没有牵头遗传性大疱性表皮松解症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 3 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南京有 5 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

东部战区总医院(金陵医院)

Jinling Hospital

南京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Nanjing Jinling Hospital; Affiliated Jinling Hospital; Jingling Hospital; Nanjing General Hospital of Nanjing Military Command; Jinling Hospital (General Hospital of Eastern Theater Command); Cancer Center of Jinling Hospital; Affiliated Jinling Hospital of Nanjing Medical University; Cancer Centre of Jinling Hospital

提出更正下载数据